Semax

Semax Nasal Spray is supplied by Crystal Peptides as a catalogued research material in the format and strength: nasal spray, 10mg/10ml. This presentation is identified separately from other Semax catalogue materials, and its composition and analytical documentation must be assessed at batch level.

Semax is a synthetic seven-residue peptide derived from the ACTH(4–7) sequence with a Pro-Gly-Pro extension: Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP. N-acetyl variants and different salt forms are distinct analytical articles. The exact termini, counter-ion and formulation composition must be matched to the batch certificate of analysis (CoA) and safety data sheet (SDS).

Chemical properties and registry information

Registry identifiers and molecular values describe the corresponding peptide entity, not the complete formulated product. Their applicability depends on the documented sequence, termini and material form; batch records take precedence over general compound listings.

Research background and published evidence

Published research

Published Semax research includes peptide identity and stability, glial-cell gene-expression models, and biophysical investigations of peptide–membrane interactions and metal coordination. These contexts concern defined experimental materials and conditions rather than validation of this catalogue presentation. The cited research background includes cellular, animal and biophysical work; it does not establish one definitive direct receptor mechanism.

Current scientific understanding

Interpretation depends on the peptide identity, experimental system and analytical endpoints used in each study. Findings concerning a differently terminated, acetylated or salted material cannot establish equivalent behaviour for this batch. Compound-level literature also does not establish the stability, composition or experimental performance of a finished formulation. No human-use suitability can be inferred from these research contexts.

Formulation note

The published research background largely concerns other experimental materials or routes rather than this specific nasal spray formulation. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. Excipients, counter-ions and the formulation matrix may affect analytical interpretation and require presentation-specific documentation. The catalogue format and stated strength do not establish equivalence to any material described in a publication.

Quality and testing

Quality information must be supported by a batch-specific CoA matching this product, presentation and lot. Documentation for another Semax size, formulation or batch is not evidence for this material. The stated catalogue strength is a product specification and should not be treated as an independently verified analytical result without the corresponding report.

Identity, chromatographic area purity, peptide content, counter-ion content, formulation composition, sterility, endotoxin and elemental impurities are separate measurements. A result for one attribute does not establish the others. Only tests explicitly documented in the matching batch report should be regarded as available; unspecified attributes remain unverified.

For laboratory research use only by qualified professionals. Not for human or veterinary use. No dosing directions are provided. Purchasers are responsible for compliance with applicable institutional and local requirements.